Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SCYNEXIS, Inc. (SCYX : NSDQ)
 
 • Company Description   
SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.

Number of Employees: 28

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.63 Daily Weekly Monthly
20 Day Moving Average: 394,021 shares
Shares Outstanding: 41.97 (millions)
Market Capitalization: $26.54 (millions)
Beta: 1.34
52 Week High: $1.48
52 Week Low: $0.57
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.47% -5.31%
12 Week -20.11% -21.40%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 EVERTRUST PLAZA 13TH FLOOR
-
JERSEY CITY,NJ 07302
USA		 ph: 201-884-5485
fax: 201-884-5490		 ikoffler@lifesciadvisors.com http://www.scynexis.com
 
 • General Corporate Information   
Officers
David Angulo - Chief Executive Officer
Ivor Macleod - Chief Financial Officer
Guy Macdonald - Director
David Hastings - Director
Steven C. Gilman - Director

Peer Information
SCYNEXIS, Inc. (GSAC)
SCYNEXIS, Inc. (CASI)
SCYNEXIS, Inc. (ALCD.)
SCYNEXIS, Inc. (OMNN)
SCYNEXIS, Inc. (CGPI.)
SCYNEXIS, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 811292200
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/11/26
Share - Related Items
Shares Outstanding: 41.97
Most Recent Split Date: 7.00 (0.10:1)
Beta: 1.34
Market Capitalization: $26.54 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.03 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/11/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 0.61
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.73
Price/Cash Flow: -
Price / Sales: 9.05
EPS Growth
vs. Year Ago Period: -183.33%
vs. Previous Quarter: -21.43%
Sales Growth
vs. Year Ago Period: -49.39%
vs. Previous Quarter: -75.51%
ROE
12/31/25 - -
09/30/25 - -60.54
06/30/25 - -43.04
ROA
12/31/25 - -
09/30/25 - -41.77
06/30/25 - -28.21
Current Ratio
12/31/25 - -
09/30/25 - 5.75
06/30/25 - 5.20
Quick Ratio
12/31/25 - -
09/30/25 - 5.75
06/30/25 - 5.20
Operating Margin
12/31/25 - -
09/30/25 - -962.76
06/30/25 - -688.92
Net Margin
12/31/25 - -
09/30/25 - -862.89
06/30/25 - -599.05
Pre-Tax Margin
12/31/25 - -
09/30/25 - -862.38
06/30/25 - -610.71
Book Value
12/31/25 - -
09/30/25 - 0.87
06/30/25 - 1.14
Inventory Turnover
12/31/25 - -
09/30/25 - -
06/30/25 - -
Debt-to-Equity
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
Debt-to-Capital
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
 

Powered by Zacks Investment Research ©